• Cite Icon42
  • https://doi.org/10.1111/j.1610-0387.2010.07482.xCopy DOI Icon

Mastocytosis – an update

Show More
  • Abstract
  • Literature Map
  • References
  • Citations
  • Similar Papers
Abstract

Mastocytosis (MC) encompasses a range of disorders characterized by a clonal, pathological accumulation of mast cells having a somatic activating mutation of the tyrosine kinase receptor Kit (exon 17, codon 816; D816V) in more than 90 % of adult patients. The mutation is much less common in children. Skin and bone marrow are most often affected. Symptoms and clinical course are very heterogeneous due to a variable degree of local or systemic mediator release or organ dysfunction as a result of mast cell infiltrates. Pruritus, wheals, flushing and gastrointestinal symptoms are often reported. The majority of pediatric patients experience spontaneous remission of MC. Adults usually have chronic disease, rarely transforming into an aggressive or lethal type. Indolent systemic MC with involvement of skin and bone is the most common type. In MC the risk for anaphylactic reactions following an insect sting (and other causes of mast cell activation) is increased significantly. Diagnostic hallmarks are biopsies from skin and bone marrow using tryptase antibodies for staining as well as serum tryptase levels. At present a curative treatment for MC is not available. Systemic histamine H(1) receptor antagonists are widely used. Aggressive types of MC respond partially to IFN-alpha or cladribine. A variety of receptor tyrosine kinase inhibitors is still under critical evaluation for systemic treatment of MC. After introduction of the WHO classification for MC and the development a German MC guideline, as well as the foundation of national and international competence networks for MC, a significantly improved quality of medical care for MC patients can be expected for the future.

Similar Papers
  • Abstract

Clinical, Biological, and Molecular Characteristics of Well-Differentiated Systemic Mastocytosis: a study in 18 Patients by Spanish Network on Mastocytosis (REMA)

  • Nov 16, 2008
  • Blood
  • Iván Alvarez-Twose +8
  • Abstract

Molecular Quantification of Tissue Mast Cell Burden in Systemic Mastocytosis: A New Approach for Diagnostics and Prognostication

  • Nov 29, 2018
  • Blood
  • Greiner Georg +11
  • Abstract
  • Citations8

Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

  • Nov 15, 2022
  • Blood
  • Cem Akin +11
  • Abstract
  • Citations1

Comprehensive Cytokine Profiling in Systemic Mastocytosis: Prognostic Relevance of Increased Plasma IL-2R Levels.

  • Nov 16, 2012
  • Blood
  • Animesh Pardanani +3
  • Research Article

The effect of bezuclastinib on the pathobiology of mastocytosis: Changes in BM mast cells, tryptase, and KIT p.D816V variant allele frequency from the pivotal summit trial

  • Nov 03, 2025
  • Blood
  • Tracy George +12
  • PDF
  • Research Article
  • Citations10

Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome

  • Apr 24, 2017
  • Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
  • Iolanda Conde-Fernandes +9
  • Abstract
  • Citations3

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

  • Nov 13, 2019
  • Blood
  • Cem Akin +26
  • Abstract

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

  • Nov 29, 2018
  • Blood
  • Ioannis Tsonis +36
  • Abstract
  • Citations1

Digital Droplet PCR: Next Generation KIT D816V Testing As Advanced Tool for Diagnosis and Prognostication in Mastocytosis

  • Jun 25, 2021
  • Blood
  • Greiner Georg +10
  • Research Article
  • Citations31

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis

  • Apr 24, 2019
  • Haematologica
  • Georg Greiner +12
  • Research Article
  • Citations80

Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology

  • Aug 15, 2000
  • Blood
  • Cem Akin +6
  • Research Article
  • Citations1

Diagnosis and management of systemic mastocytosis in a community hematology setting.

  • Dec 27, 2023
  • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • George Dranitsaris +6
  • Research Article

Real-world characteristics of systemic mastocytosis in Romania: insights from a reference-center-based descriptive study.

  • Jul 01, 2025
  • Journal of medicine and life
  • Horia Bumbea +8
  • Abstract
  • Citations1

LONG TERM TREATMENT OF SYSTEMIC MASTOCYTOSIS WITH OMALIZUMAB

  • Nov 01, 2018
  • Annals of Allergy, Asthma & Immunology
  • G Carlson +1
  • Research Article
  • Citations1

A Vertebral Fracture Unmasking Systemic Mastocytosis in a 29-Year-Old Man

  • Feb 19, 2024
  • AACE Clinical Case Reports
  • Christopher Nguyen +4
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.